MedTrace Logo

Use of Allocetra-OTS in End Stage Knee Osteoarthritis - Assessment of Safety

NCT06208241 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-04-13

No results posted yet for this study

Summary

This is a pilot study to assess safety and possible efficacy of Allocetra-OTS in end-stage knee osteoarthritis.

Conditions

Interventions

DRUG

Allocetra-OTS

Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state and suspended in a solution containing DMSO.

Sponsors & Collaborators

  • Enlivex Therapeutics Ltd.

    collaborator INDUSTRY

  • Amir Oron

    lead OTHER

Principal Investigators

  • Amir Oron, MD · Kaplan Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-12
Primary Completion
2026-09-25
Completion
2026-12-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06208241 on ClinicalTrials.gov